C ommon chronic diseases, such as hypertension and diabetes, are referred to as "silent epidemics." This term is relevant to chronic kidney disease (CKD), which manifests without overt symptoms in most patients. Timely identification through laboratory criteria is necessary to enable patients, providers, and health systems to triage, treat, and prevent the progression of CKD. 1 Although up to 1 in 7 Americans has CKD, only 10% of patients with CKD stage 3 and 40% with CKD stage 4 are aware of their diagnosis. 2,3 A CKD diagnosis requires 2 assessments of estimated glomerular filtration rate (eGFR) separated by at least 90 days. 4 Although the US Preventive Services Task Force has found insufficient evidence for screening CKD in the general population, KDIGO has recommended screening in high-risk populations, including patients with diabetes, hypertension, cardiovascular disease, structural renal tract disease, and systemic illness affecting the kidneys (HIV, lupus, vasculitis, rheumatoid arthritis, hyperuricemia, and multiple myeloma). 2,4 Diagnosing CKD in the early stages has synergistic benefits because it enables improved management of CKD and of risk factors that cause or worsen CKD. 5 Managing comorbid conditions can prevent or delay progression to chronic kidney failure and reduce cardiovascular disease risk. 6 Early identification, staging, and risk stratification enable timely referrals to nephrology, increased use of therapies such as reninangiotensin-aldosterone system blockers and SGLT2 inhibitors that can delay CKD progression, and planning for chronic kidney failure, including permanent vascular or peritoneal dialysis access placement, transplantation referrals, and decision making around conservative management in patients for whom kidney replacement therapy may not be the best option. 7,8 With regard to targeted screening, a question has arisen in an era of large data collection through electronic health records (EHRs): What is the best way to follow up on abnormal eGFR results to diagnose incident cases of CKD? This is a particularly relevant question when for most patients, CKD is diagnosed and managed by primary care providers (PCPs), who manage a multitude of conditions and balance competing priorities. In this issue of AJKD, Danforth et al 9 report a mixed-methods study examining patient, provider, and system-level factors associated with care gaps in the follow-up of abnormal eGFRs in an integrated health care system.